

Available online at www.sciencedirect.com

Metabolism

www.metabolismjournal.com

Review

The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes

Anand Vaidya*, Jonathan S. Williams

Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA

ARTICLE INFO

Article history:

Received 15 August 2011

Accepted 21 September 2011

ABSTRACT

Vitamin D has been implicated in the pathophysiology of extraskeletal conditions such as hypertension, kidney disease, and diabetes via its ability to negatively regulate the renin-angiotensin system (RAS). This article reviews the evidence supporting a link between vitamin D and the RAS in these conditions, with specific emphasis on translational observations and their limitations. A literature review of animal and human studies evaluating the role of vitamin D in hypertension, kidney disease, and diabetes was performed. Excess activity of the RAS has been implicated in the pathogenesis of hypertension, chronic kidney disease, decreased insulin secretion, and insulin resistance. Animal studies provide strong support for 1,25-dihydroxyvitamin D₃-mediated downregulation of renin expression and RAS activity via its interaction with the vitamin D receptor. Furthermore, the activity of vitamin D metabolites in animals is associated with reductions in blood pressure, proteinuria and renal injury, and with improved β -cell function. Many observational, and a few interventional, studies in humans have supported these findings; however, there is a lack of well-designed prospective human interventional studies to definitively assess clinical outcomes. There is a need for more well-designed prospective interventional studies to validate this hypothesis in human clinical outcomes.

© 2012 Elsevier Inc. All rights reserved.

1. Introduction

Vitamin D is an important mediator of calcium metabolism and skeletal health that is acquired and synthesized from dietary sources and ultraviolet radiation. It has also been implicated as a potential contributor to the pathophysiology of extraskeletal conditions, including hypertension, kidney disease, and insulin resistance [1–5]. The key clinical barometer of human vitamin D status is 25-hydroxyvitamin D (25[OH]D), which is converted to the active vitamin D metabolite 1,25-

dihydroxyvitamin D (1,25[OH]₂D) via the sensitively regulated action of the 1 α -hydroxylase enzyme [1]. Because 25(OH)D is a stable metabolite that is easier to quantify than 1,25(OH)₂D, it is often evaluated in studies as a measure of vitamin D effect; however, it is 1,25(OH)₂D that is the active vitamin D receptor (VDR) agonist. When liganded with 1,25(OH)₂D, the VDR can dimerize with the retinoid X receptor to become a transcription factor that may influence the expression of hundreds of genes [6,7]. In addition, the 1,25(OH)₂D-VDR complex has been associated with several nongenomic cellular pathways [7].

Author contributions: Both authors contributed equally to the research and writing of this manuscript.

* Corresponding author.

E-mail address: avaidya1@partners.org (A. Vaidya).

0026-0495/\$ – see front matter © 2012 Elsevier Inc. All rights reserved.

doi:10.1016/j.metabol.2011.09.007

The renin-angiotensin system (RAS) plays a crucial role in the physiology of sodium and volume homeostasis [8]; however, excess activity of the RAS is associated with cardiometabolic diseases such as hypertension, kidney disease, and diabetes [9,10]. In addition to the circulating RAS, the pathophysiology associated with the RAS is likely mediated by the many locally expressed tissue RASs that have been identified in tissues such as the kidney, vascular endothelium, pancreas, cardiac tissue, and adipose tissue [11]. To date, a strong body of evidence supports vitamin D as a negative regulator of the circulating and local tissue RAS [2,12]. Although other mechanisms implicating vitamin D in the pathogenesis of disease exist, this review will specifically examine the influence of the relationship between vitamin D and the RAS on (1) blood pressure control and incident hypertension, (2) kidney function and chronic kidney disease (CKD), and (3) insulin sensitivity and incident diabetes. In particular, novel translational research that has provided basic science evidence for a relationship between vitamin D and the RAS will be highlighted, along with clinical observations from human investigations.

2. Vitamin D and hypertension

Vitamin D metabolites have been associated with the regulation of blood pressure, and hormonal mechanisms regulating blood pressure, for decades [13,14]. Observational reports have noted higher blood pressure trends in winter months and locations further from the equator, suggesting that low ultraviolet radiation and thus decreased capacity for cutaneous vitamin D synthesis are associated with hypertension [15]. The most notable mechanism implicating vitamin D with hypertension is its role as a negative regulator of the RAS [16]; other notable hypotheses have suggested that vitamin D influences vascular endothelial function [17–21] or vascular smooth muscle intracellular calcium concentrations [13,14,22]. Because inappropriately elevated activity of the RAS contributes to hypertension and cardiovascular risk [23–25], many observational and interventional studies have focused on investigating the role of vitamin D metabolites in the development of hypertension.

The most convincing mechanistic studies linking vitamin D with RAS activity and blood pressure regulation were conducted in animal models. Li et al [16] showed that VDR-knockout (KO) mice had significant elevations in renin activity and circulating plasma angiotensin II concentrations [26]. These mice developed hypertension and cardiac hypertrophy that could be attenuated with the administration of RAS antagonist pharmacotherapy, and also exhibited increased activity of the local cardiac tissue RAS [16,27]. In parallel, a mouse model of 1α -hydroxylase deficiency (inability to synthesize $1,25(\text{OH})_2\text{D}$) also exhibited a phenotype of enhanced RAS activity, hypertension, and cardiac hypertrophy that was attenuated with the administration of $1,25(\text{OH})_2\text{D}$ or RAS antagonists [28]. The collective work by these investigators has shown that $1,25(\text{OH})_2\text{D}$ -liganded VDR acts to suppress renin gene expression [29,30], suggesting that VDR agonists could exhibit protective effects on blood pressure and cardiac tissue. Corollary human physiology studies have shown that lower

levels of $1,25(\text{OH})_2\text{D}$ and $25(\text{OH})\text{D}$ are associated with higher plasma renin activity, higher angiotensin II concentrations, and higher systemic vascular-tissue RAS activity [13,31–33].

Most human clinical studies evaluating the role of vitamin D on blood pressure have been cross-sectional analyses [2,34]. The majority of these yielded results that were consistent with the animal data in showing an inverse association between vitamin D and blood pressure [35–37] or prevalent hypertension [38,39]. In contrast, at least 2 cross-sectional studies demonstrated no detectable association between vitamin D and blood pressure or the prevalence of hypertension [40,41]; however, in addition to the traditional limitations of cross-sectional analyses, these conflicting results may have been confounded by comparatively high $25(\text{OH})\text{D}$ concentrations and prevalent use of antihypertensive medications that could obscure potential associations [40,41].

Longitudinal and prospective studies evaluating $25(\text{OH})\text{D}$ levels have similarly shed mixed results. In a prospective longitudinal analysis of 613 men from the Health Professionals' Follow Up Study and 1198 women from the Nurses' Health Study followed for 4 to 8 years, Forman et al [42] observed a pooled adjusted relative risk for incident hypertension of 3.18 (95% confidence interval [CI], 1.39–7.29) in individuals with lower (<15 ng/mL) vs higher (30 ng/mL) concentrations of $25(\text{OH})\text{D}$. The same authors subsequently performed a nested case-control analysis with normotensive women from the Nurses' Health Study and observed an adjusted odds ratio for incident hypertension of 1.66 (P trend = .01) when comparing those with $25(\text{OH})\text{D}$ levels in the lowest vs highest quartiles [43]. In the longitudinal Michigan Bone Health and Metabolism Study, Griffin et al [44] evaluated the risk for systolic hypertension over 14 years in 559 white women who had $25(\text{OH})\text{D}$ and blood pressure measures in 1993 and again in 2007. Although they observed no cross-sectional association between $25(\text{OH})\text{D}$ concentrations and concurrent blood pressure in 1993, $25(\text{OH})\text{D}$ concentrations of less than 32 ng/mL in 1993 were significantly associated with an increased risk for systolic hypertension in 2007 (adjusted odds ratio, 3.0; 95% CI, 1.01–8.7). In contrast, Jorde et al [45] reported conflicting observations from the Tromso study that followed individuals for 14 years (1994–2008) who were naive to antihypertensive therapy. Although an inverse cross-sectional association between systolic blood pressure and quartiles of $25(\text{OH})\text{D}$ was noted at baseline in 1994, $25(\text{OH})\text{D}$ concentrations from 1994 did not predict incident hypertension or future blood pressure. Whether these inconsistent observations were due to the lack of sufficient range in $25(\text{OH})\text{D}$ concentrations within the study populations or other unrecognized confounding, they highlighted the need for definitive randomized controlled studies.

Interventional studies evaluating controlled ultraviolet exposure have also shown mixed results; Krause et al [46] observed mild blood pressure reductions in untreated hypertensives, whereas Scragg et al [47] observed no change in a largely normotensive population. Both of these studies were well designed, with significant increases in $25(\text{OH})\text{D}$ levels following ultraviolet therapy; however, they may have been limited by durations of follow-up that were too short to detect pathological changes in arterial function (6 and 12 weeks, respectively) and by relatively small sample sizes.

To date, more than 10 interventional studies involving vitamin D therapy in non-blood pressure primary outcomes have explored the effect of vitamin D therapy on blood pressure [2,48–58]. The majority of these studies did not find a significant relationship between vitamin D supplementation and blood pressure or incident hypertension. The largest of these studies was the Women's Health Initiative ($n = 36\,282$), designed to evaluate whether 400 IU of daily vitamin D₃ with calcium supplementation reduced fracture and cancer risk when compared with placebo in a population of largely vitamin D-insufficient women [55]. After 7 years of follow-up, no change in blood pressure or incident hypertension was observed. The interpretation of these results was limited by modest vitamin D₃ supplementation in the intervention arm and a high rate of non-study-related vitamin D supplementation in the placebo group. The second largest of these studies ($n = 438$) was designed to evaluate the effect of vitamin D₃ supplementation on weight loss and included overweight and obese individuals, but did not exclude the use of antihypertensive medications [56]. After 1 year of randomization to vitamin D₃ 40 000 or 20 000 IU/wk or to placebo, no change in blood pressure was observed. Because 25(OH)D levels in this study rose from a baseline of less than 30 ng/mL to greater than 50 ng/mL in the 40 000-IU/wk group, these data argued that reasonable elevations in 25(OH)D did not influence blood pressure. On the other hand, whether a 1-year follow-up was sufficient to detect blood pressure outcomes or whether a largely obese population with heterogeneous antihypertensive medication use was the ideal study population is debatable. Only 2 prospective randomized trials to date have been designed to evaluate blood pressure as the primary end point in a population maintained free of antihypertensive therapy [57,58] and have revealed mixed results. The first showed that a single dose of vitamin D₃ 100 000 IU in a vitamin D-deficient population did not lower blood pressure after 5 weeks when compared with placebo [57], but the short duration and modest 7-ng/mL rise in 25(OH)D levels (from a baseline of 13 ng/mL) limit the convincibility of a negative result. In the second study, elderly 25(OH)D-deficient women who received vitamin D₃ 800 IU/d for 8 weeks had a significant, but modest, decline in systolic blood pressure (–7 mm Hg) when compared with those who received placebo [58]; however, the short duration of follow-up and small sample size ($n = 148$) limit the strength and interpretation of these positive results as well.

As the majority of human clinical data stem from cross-sectional or interventional studies with notable design limitations, there is a need for definitive large-scale randomized controlled trials designed to optimally evaluate the influence of vitamin D therapy on blood pressure. Ideally, future interventional studies should have sufficient sample size, longer duration of follow-up, higher vitamin D metabolite supplementation doses, and restriction of antihypertensive drug use, while controlling for confounders of the RAS. Meta-analyses have attempted to aggregate prior trial findings, including many of the aforementioned [59–62]. Witham et al [59] were able to detect a blood pressure-lowering effect associated only when limiting their analyses to those studies that focused on hypertensive individuals, whereas Pittas et al [60] were able to detect effects using studies with higher doses of vitamin D₃ supplementation (>1000 IU/d). The meta-analysis by Burgaz et al [61] detected a

reduced odds of hypertension when comparing the highest category of 25(OH)D concentration to the lowest (odds ratio, 0.73; 95% CI, 0.63–0.84). In contrast, Elamin et al [62] detected no blood pressure-lowering effect in a meta-analysis evaluating cardiovascular outcomes. The Vitamin D and Omega-3 Trial (VITAL) (NCT 01169259) is a large randomized controlled trial ($n = 20\,000$) in the United States that opened for recruitment in late 2010 and aims to evaluate the impact of vitamin D₃ supplementation (2000 IU/d) on cardiovascular and cancer outcomes over 5 years. The size, duration of follow-up, and higher vitamin D₃ doses in this study design may allow sufficient power and effect size to examine the influence of long-term vitamin D₃ supplementation on blood pressure.

3. Vitamin D and kidney disease

The development of hypertension and kidney disease is often interrelated, yet vitamin D has been implicated as renoprotective independent of its potential effect on blood pressure. In normal physiology, 1,25(OH)₂D acts to lower parathyroid hormone; the standard use of VDR agonists in CKD to lower parathyroid hormone levels for the management of the calcium-phosphate product and renal osteodystrophy is well established. Whereas prior hypotheses have suggested that parathyroid hormone may directly influence vascular function and blood pressure [63–65], this discussion will focus specifically on the novel independent effects vitamin D metabolites may have on the RAS and consequently renal function and progression of kidney disease [28,66].

As in the case of hypertension, the most prominent mechanism explaining the role of vitamin D in kidney disease has been its negative regulation of the RAS in animal models. In addition to elevations in circulating RAS components, VDR-KO mice also display increased expression of renal-vascular renin messenger RNA [16]. When subjected to a model of renal injury consisting of unilateral ureteral obstruction, these animals demonstrated more severe kidney injury and fibrosis in the obstructed kidney when compared with wild type mice [67]. The administration of an angiotensin-receptor antagonist attenuated the observed injury, suggesting that reduced signaling through the VDR resulted in unfavorably high intrarenal RAS activity and obstructive renal injury. In addition, 1 α -hydroxylase-deficient mice exhibit increased activity of the intrarenal RAS that is downregulated with the administration of 1,25(OH)₂D [28]. In support of prior hypotheses that VDR agonists negatively regulate renin expression [30], treatment of diet-induced obese mice with doxercalciferol (1 α -hydroxyvitamin D₂) lowered the expression of intrarenal renin and angiotensin II type 1 receptors, with concurrent decrements in proteinuria, podocyte injury, mesangial expansion, and inflammation [68]. Three different mouse models of diabetes (streptozocin-induced [type 1], and *db/db* or *KK-A^y/Ta* [type 2]) have been observed to develop proteinuria and renal injury with elevated intrarenal RAS activity in untreated animals [69–71]. These mice exhibited lowering of RAS activity and attenuation of proteinuria and kidney injury when treated with a VDR agonist alone (1,25 [OH]₂D or paracalcitol) or an angiotensin-receptor blocker alone, but synergistically improved outcomes when the

combination of the two was used [69–71]. In addition to reducing intrarenal renin and RAS activity in these experiments, VDR agonist treatment was observed to inhibit the transforming growth factor (TGF)- β and p-ERK1/2 systems, implicating other potential pathways by which VDR agonists induce renoprotection. Corollary human mechanistic studies have reported that lower 25(OH)D concentrations are associated with impairments in glomerular filtration rate [72,73] and higher renal-vascular RAS activity [74]. The Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function (MODERATE) (NCT 01320722), currently enrolling subjects in the United States, aims to further characterize the biological relationship between vitamin D and the renal-vascular RAS in humans by evaluating renal RAS activity and renal plasma flow before and after randomization to 8 weeks of vitamin D₂ 50 000 IU/wk or placebo.

The majority of human clinical studies have investigated the role of vitamin D in patients with established CKD of varying stages, a condition usually confounded by 1,25(OH)₂D insufficiency or deficiency, elevated parathyroid hormone levels, and concurrent hypertension. Observational studies have shown cross-sectional associations between lower 25(OH)D concentrations and the prevalence of CKD [75,76] and proteinuria [77]. These cross-sectional findings are limited by their inability to predict direction of change or causality of these relationships. In contrast, a recent systematic review and meta-analysis of 22 studies (17 observational and 5 randomized trials) of vitamin D₂ or D₃ supplementation suggested that, although these interventions expectedly raised 25(OH)D and lowered parathyroid hormone levels in CKD, they did not significantly affect other biochemical markers of kidney disease progression [78]. Most of the studies included in this aggregate analysis were not designed to evaluate outcomes of disease progression; and because CKD is a state of insufficient 1 α -hydroxylase activity, the effectiveness of vitamin D₂ or D₃ supplementation on any outcome is debatable. On the other hand, Ravani et al [79] observed an inverse and independent longitudinal relationship between 25(OH)D concentrations and the progression of kidney disease in 168 individuals with non-dialysis-dependent CKD (stages 2–5) over 2 years. The use of VDR agonists among non-dialysis- and dialysis-dependent CKD patients has also been associated with an improved survival benefit in several studies; but these studies were not designed to evaluate whether the underlying mechanism for improved survival was due to intrarenal RAS regulation, parathyroid and calcium metabolism, or other reasons [80–85].

To date, there have been several interventional studies evaluating the renoprotective benefits of VDR agonist therapy in patients with CKD [86–90]. These studies have provided strong evidence to support the aforementioned animal data demonstrating a reduction in surrogate biochemical measures of fulminate renal failure (such as proteinuria) with vitamin D therapy [69–71]. However, they were not designed to examine whether vitamin D therapy delays the progression of CKD or whether it may have a role in the primary prevention of kidney disease. Agarwal et al [86] aggregately evaluated 220 patients with CKD (stages 3 or 4) from 3 randomized placebo-controlled studies evaluating the effect of paracalcitol therapy vs placebo for up to 6 months. Half of the proteinuric subjects receiving paracalcitol experienced reductions in automated dipstick

proteinuria, in comparison to only a quarter of those receiving placebo ($P < .01$). This finding was independent of many confounding factors, including the use of RAS-specific antihypertensive agents, but may have been limited by the quantification of proteinuria via an automated dipstick assay. Similarly, in 2 smaller studies, Alborzi et al [87] and Szeto et al [88] reported reductions in proteinuria with short-duration VDR agonist administration. The former randomized 24 individuals with CKD stage 3 to placebo, 1 μ g/d of paracalcitol, or 2 μ g/d of paracalcitol for 1 month and observed reductions in C-reactive protein and albuminuria in the group with higher paracalcitol dose [87]. The latter study evaluated 10 patients with IgA nephropathy who had proteinuria despite using RAS antagonist pharmacotherapy; within 6 weeks of receiving calcitriol 0.5 μ g twice weekly, a 25% decrease in urine protein-to-creatinine ratio was observed ($P < .01$) [88]. These investigators, along with Kim et al [91] who observed reduced albuminuria with vitamin D₃ supplementation in diabetes, also observed a proportional reduction in TGF- β in individuals with reduced proteinuria, mimicking the aforementioned findings in mice that received paracalcitol [69]. The findings by Fishbane et al [89] largely supported these studies when they observed a 17% ($P < .05$) reduction in proteinuria among 61 patients with CKD randomized to either paracalcitol or placebo for 6 months.

The most recent interventional study demonstrates perhaps the strongest correlation of human to animal data. In a multinational double-blind placebo-controlled trial, de Zeeuw and colleagues [90] randomized 281 patients with type 2 diabetes mellitus and albuminuria, who were on pharmacologic RAS antagonist therapy, to placebo, paracalcitol 1 μ g/d, or paracalcitol 2 μ g/d for 6 months. Participants treated with paracalcitol 2 μ g/d (in addition to RAS-antagonist therapy) experienced a steady 18% to 28% decrease in the urinary albumin-to-creatinine ratio when compared with those who received placebo (the primary end point). In concert with the reductions in albuminuria and renal injury seen with combined VDR agonists and RAS-antagonist therapy in diabetic mice [69–71], the results by de Zeeuw et al strongly support the use of VDR-agonists in combination with anti-RAS pharmacotherapy to lower proteinuria in diabetic nephropathy. Notably, although this study evaluated a strong surrogate of progressive CKD (proteinuria), it did not evaluate long-term outcomes such as the time to progression of disease or dialysis; nor was it designed to investigate whether the mechanism of the beneficial effects of paracalcitol 2 μ g/d was due to incremental RAS antagonism, synergistic inhibition of the TGF pathway, or other biological mechanisms. A better understanding of these queries could have significant implications for the potential use of vitamin D analogues in the primary prevention of kidney disease in diabetes or continued use in CKD in combination with other pharmacotherapies.

4. Vitamin D and diabetes

Vitamin D has been associated with β -cell function, peripheral insulin sensitivity, incident diabetes, and mortality in diabetes [92,93]. However, definitive human clinical trial evidence to support vitamin D supplementation in improving glycemic control or delaying the onset of diabetes is lacking and is

further hampered by inconsistent findings in human studies with limited study designs. As in the case of hypertension and kidney disease, one of the main putative mechanisms linking vitamin D to glucose control is its regulation of the RAS. The intrapancreatic and circulating RAS are known to negatively affect β -cell function and peripheral insulin sensitivity; it is speculated that the downregulation of the RAS by vitamin D may mediate its beneficial effects on glycemic control and diabetes [10,94–96].

Animal studies and in vitro experiments have provided evidence supporting the deleterious activation of the pancreatic islet cell RAS by hyperglycemia [97–99] and the resultant islet cell dysfunction and diminished β -cell mass consequent to higher local RAS activity. Activity of the pancreatic islet cell RAS is enhanced in animal models of diabetes, whereas the administration of RAS antagonists improves β -cell function, decreases oxidative stress, and prevents islet fibrosis and apoptosis [100–102]. These basic research experiments may in part explain the improved glycemic control or reduced incidence of diabetes associated with RAS antagonists in some human clinical trials and meta-analyses [103–106]. Cheng et al [107] observed increased pancreatic islet RAS expression in VDR-KO mice. Furthermore, 2 separate investigations have shown that, in the presence of 1,25(OH)₂D, islet cells from wild-type mice demonstrate attenuated local RAS production and improved insulin secretion [10,107]. Together, these findings suggest that antagonism of the local pancreatic islet RAS may improve β -cell function and mass, and that VDR agonists may improve insulin secretion via negative regulation of renin expression [107].

There is an abundance of human clinical studies examining the potential link between levels of vitamin D metabolites (or vitamin D intake) with glycemic control and the incidence of diabetes. Unfortunately, the majority are either inconclusive cross-sectional associations or not designed to specifically assess these end points. Furthermore, the study of type 1 and type 2 diabetes mellitus may not be immediately comparable because the pathophysiology of the 2 conditions are distinct. The EUROpe and DIABetes (EURODIAB) EURODIAB case-control study found that vitamin D supplementation in infancy (by historical questionnaire) reduced the odds of developing type 1 diabetes mellitus (adjusted odds ratio, 0.67; 95% CI, 0.53–0.86) [108]. Similarly, in a Finnish birth cohort ($n = 12\,231$) that was followed until age 30 years, infants who received the recommended vitamin D₃ 2000 IU/d during the first year of life had a relative risk of 0.22 (95% CI, 0.05–0.89) for developing type 1 diabetes mellitus when compared with those who received less [109]. Although both studies support the potential immunomodulatory effect of vitamin D [110], they were limited by their retrospective study designs and small number of cases developing type 1 diabetes mellitus during follow-up. In contrast, longitudinal analyses in the Diabetes Autoimmunity Study in the Young study found no association between 25(OH)D levels or vitamin D intake with islet autoimmunity or progression to type 1 diabetes in 2644 children [111]. To date, large-scale prospective studies evaluating the effect of vitamin D therapy on the incidence of type 1 diabetes have not been performed.

Cross-sectional studies evaluating type 2 diabetes mellitus have also provided inconclusive results. Scragg et al [112]

evaluated more than 6000 individuals from the National Health and Nutrition Examination Survey and found that lowest-quartile 25(OH)D levels were associated with a diagnosis of diabetes by fasting blood glucose when compared with those in the highest quartile; however, this observation was only seen when excluding non-Hispanic blacks ($n = 1736$). Other analyses of large cohorts have demonstrated significant inverse associations between vitamin D metabolites and glycated hemoglobin [113], the prevalence of diabetes [114], and the 5-year incidence of developing diabetes [115]. Studies evaluating vitamin D in the mechanism of type 2 diabetes mellitus have observed that 25(OH)D concentrations are positively associated with adiponectin (a circulating peptide that promotes insulin sensitivity) [116], but these studies were not designed to evaluate whether insulin sensitivity was consequently affected [117–120]. Muscogiuri et al [121] reported perhaps the strongest negative human mechanistic evidence to date. In 39 nondiabetic individuals who underwent hyperinsulinemic-euglycemic clamp, 25(OH)D concentrations were not associated with peripheral insulin sensitivity after adjustment for notable confounders, such as body mass index. This study highlights one of the 2 major confounders when evaluating for a true causal relationship between vitamin D and diabetes. The first is that body mass index is a critical predictor of both 25(OH)D and diabetes [122]; thus, it may bias analyses toward rejecting the null hypothesis. The second is that dietary sodium intake acutely modifies insulin sensitivity [123–125] and activity of the RAS (a putative mediator of the relationship between vitamin D and diabetes). Therefore, prospective interventional studies with randomization and controlled dietary sodium conditions are needed to thoroughly evaluate for a causal relationship between vitamin D and insulin sensitivity or incident diabetes.

Prospective and longitudinal studies have shed mixed results. In a Finnish cohort study following more than 4000 nondiabetic patients for 17 years, Mattila et al [126] encountered 187 new cases of type 2 diabetes mellitus. Although the relative risk for developing diabetes between the highest and lowest quartile of 25(OH)D after multivariate adjustment was suggestive of a protective effect (relative risk = 0.70), the result was not statistically significant (P trend = .07). In contrast, at least 6 other longitudinal assessments have reported a significant inverse association between 25(OH)D concentrations and future severity of insulin resistance and/or incidence of diabetes [115,127–131].

To date, interventional studies have largely refuted the theory that vitamin D may benefit insulin sensitivity; however, it is important to note that they were not designed to specifically examine this question. In the Women's Health Initiative, postmenopausal women were randomized to receive a low dose of vitamin D₃ (400 IU/d) or placebo [132]. After a mean follow-up time of 7 years, the hazard for incident type 2 diabetes mellitus was 1.01 (95% CI, 0.94–1.10), suggesting a null effect. In 2 distinct randomized placebo-controlled intervention studies, Jorde et al [133] used significantly higher doses of vitamin D₃ 40 000 IU/wk and found (1) no improvement in glycemic control in 32 type 2 diabetes mellitus patients already prescribed metformin and insulin who were treated for 6 months and (2) no improvement in glucose

tolerance in 330 nondiabetic individuals treated for 1 year [56]. In contrast, 2 smaller placebo-controlled interventional studies recently reported significant improvements in homeostatic model assessment for insulin resistance in 42 South Asian women receiving vitamin D₃ 4000 IU/d for 6 months [134], and fasting blood glucose and glycated hemoglobin in type 2 diabetes mellitus receiving vitamin D-fortified yogurt drinks for 3 months [135]. The results of each of these interventional studies (whether positive or negative in outcome) are limited in part by a combination of short duration of follow-up, inadequate power and study design to detect the outcome of interest, insufficient dose of vitamin D, and potentially uncontrolled dietary sodium intake during assessments of insulin sensitivity. Systematic reviews and meta-analyses have attempted to address these limitations with aggregate pooled evaluations, but have concluded that there are currently insufficient human data to strongly support a link between vitamin D and diabetes [60,136].

5. Summary and future directions

Recent translational research has implicated 1,25(OH)₂D, via its interaction with the VDR, in the pathophysiology of hypertension, progressive kidney disease, and diabetes. Although the contribution of the RAS in the development of these conditions is known, novel basic animal experiments have provided evidence to support the negative regulation of the RAS by VDR agonism in mediating these associations. Whereas some human mechanistic studies have supported these animal data, many have provided inconsistent conclusions. Future intervention studies designed to definitively evaluate the clinical utility of vitamin D therapy will need to identify whether the focus of investigation should be on primary prevention or attenuated progression of disease. In addition, future trials must consider study designs with adequate power and sample size, the optimal vitamin D metabolite for intervention (vitamin D₂/D₃, 1,25(OH)₂D or other VDR agonist), and potentially dietary sodium control (for baseline and end point assessments) to avoid confounding by the RAS.

Funding

F32HL104776 (AV) and K23HL08236-03 (JSW). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of Interest

None.

REFERENCES

- [1] Holick MF. Vitamin D deficiency. *N Engl J Med* 2007;357:266-81.
- [2] Vaidya A, Forman JP. Vitamin D and hypertension: current evidence and future directions. *Hypertension* 2010;56:774-9.
- [3] Patel TV, Singh AK. Role of vitamin D in chronic kidney disease. *Semin Nephrol* 2009;29:113-21.
- [4] Baz-Hecht M, Goldfin AB. The impact of vitamin D deficiency on diabetes and cardiovascular risk. *Curr Opin Endocrinol Diabetes Obes* 2010;17:113-9.
- [5] Li HW, Brereton RE, Anderson RA, et al. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. *Metabolism* 2011.
- [6] Ramagopalan SV, Heger A, Berlanga AJ, et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. *Genome Res* 2010;20:1352-60.
- [7] Haussler MR, Jurutka PW, Mizwicki M, et al. Vitamin D receptor (VDR)-mediated actions of 1α,25(OH)₂vitamin D(3): genomic and non-genomic mechanisms. *Best Pract Res Clin Endocrinol Metab* 2011;25:543-59.
- [8] Young WF. *Endocrine hypertension*, Williams textbook of endocrinology, vol. 11th ed., 2008.
- [9] Stiefel P, Vallejo-Vaz AJ, Garcia Morillo S, et al. Role of the renin-angiotensin system and aldosterone on cardiometabolic syndrome. *Int J Hypertens* 2011;2011:685238.
- [10] Leung PS. Current research of the RAS in diabetes mellitus. *Adv Exp Med Biol* 2010;690:131-53.
- [11] Bader M. Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. *Annual Review of Pharmacology and Toxicology* 2010;50:439-65.
- [12] Li YC. Inhibition of renin: an updated review of the development of renin inhibitors. *Curr Opin Investig Drugs* 2007;8:750-7.
- [13] Resnick LM, Muller FB, Laragh JH. Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. *Ann Intern Med* 1986;105:649-54.
- [14] Resnick LM. Calcitropic hormones in salt-sensitive essential hypertension: 1,25-dihydroxyvitamin D and parathyroid hypertensive factor. *J Hypertens Suppl* 1994;12:S3-9.
- [15] Rostand SG. Ultraviolet light may contribute to geographic and racial blood pressure differences. *Hypertension* 1997;30:150-6.
- [16] Li YC, Kong J, Wei M, et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. *J Clin Invest* 2002;110:229-38.
- [17] Tarcin O, Yavuz DG, Ozben B, et al. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. *J Clin Endocrinol Metab* 2009;94:4023-30.
- [18] Harris RA, Pedersen-White J, Guo D-H, et al. Vitamin D3 supplementation for 16 weeks improves flow-mediated dilation in overweight African-American adults. *Am J Hypertens* 2011.
- [19] Jablonski KL, Chonchol M, Pierce GL, et al. 25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. *Hypertension* 2010.
- [20] Yiu YF, Chan YH, Yiu KH, et al. Vitamin D deficiency is associated with depletion of circulating endothelial progenitor cells and endothelial dysfunction in patients with type 2 diabetes. *J Clin Endocrinol Metab* 2011;96:E830-5.
- [21] Al Mheid I, Patel R, Murrow J, et al. Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans. *J Am Coll Cardiol* 2011;58:186-92.
- [22] Shan J, Resnick LM, Lewanczuk RZ, et al. 1,25-Dihydroxyvitamin D as a cardiovascular hormone. Effects on calcium current and cytosolic free calcium in vascular smooth muscle cells. *Am J Hypertens* 1993;6:983-8.
- [23] Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. *N Engl J Med* 2004;351:33-41.
- [24] Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular

- events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med* 2000;342:145-53.
- [25] Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med* 1999;341:709-17.
- [26] Bouillon R, Carmeliet G, Verlinden L, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. *Endocr Rev* 2008;29:726-76.
- [27] Xiang W, Kong J, Chen S, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. *Am J Physiol Endocrinol Metab* 2005;288:E125-32.
- [28] Zhou C, Lu F, Cao K, et al. Calcium-independent and 1,25(OH)₂D₃-dependent regulation of the renin-angiotensin system in 1α-hydroxylase knockout mice. *Kidney Int* 2008;74:170-9.
- [29] Yuan W, Pan W, Kong J. 1,25-Dihydroxyvitamin D₃ suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. *J Biol Chem* 2007;282:29821-30.
- [30] Li YC. Vitamin D regulation of the renin-angiotensin system. *J Cell Biochem* 2003;88:327-31.
- [31] Vaidya A, Forman JP, Williams JS. Vitamin D and the vascular sensitivity to angiotensin II in obese Caucasians with hypertension. *J Hum Hypertens* 2010.
- [32] Tomaschitz A, Pilz S, Ritz E, et al. Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system The Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. *Clin Chim Acta* 2010.
- [33] Vaidya A, Forman JP, Seely EW, et al. 25-Hydroxyvitamin D is associated with plasma renin activity and the pressor response to dietary sodium intake in Caucasians. *J Renin Angiotensin Aldosterone Syst* 2011 [epub ahead of print].
- [34] Pilz S, Tomaschitz A, Ritz E, et al. Vitamin D status and arterial hypertension: a systematic review. *Nat Rev Cardiol* 2009.
- [35] Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the third National Health and Nutrition Examination Survey. *Am J Hypertens* 2007;20:713-9.
- [36] Hypponen E, Boucher BJ, Berry DJ, et al. 25-Hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a cross-sectional study in the 1958 British Birth Cohort. *Diabetes* 2008;57:298-305.
- [37] Judd SE, Nanes MS, Ziegler TR, et al. Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey. *Am J Clin Nutr* 2008;87:136-41.
- [38] Hintzpeter B, Mensink GB, Thierfelder W, et al. Vitamin D status and health correlates among German adults. *Eur J Clin Nutr* 2008;62:1079-89.
- [39] Burgaz A, Byberg L, Rautiainen S, et al. Confirmed hypertension and plasma 25(OH)D concentrations amongst elderly men. *J Intern Med* 2011;269:211-8.
- [40] Reis JP, von Muhlen D, Kritiz-Silverstein D, et al. Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. *Diabetes Care* 2007;30:1549-55.
- [41] Snijder MB, Lips P, Seidell JC, et al. Vitamin D status and parathyroid hormone levels in relation to blood pressure: a population-based study in older men and women. *J Intern Med* 2007;261:558-65.
- [42] Forman JP, Giovannucci E, Holmes MD, et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. *Hypertension* 2007;49:1063-9.
- [43] Forman JP, Curhan GC, Taylor EN. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. *Hypertension* 2008;52:828-32.
- [44] Griffin FC, Gadegbeku CA, Sowers MR. Vitamin D and subsequent systolic hypertension among women. *Am J Hypertens* 2010;24:316-21.
- [45] Jorde R, Figenschau Y, Emaus N, et al. Serum 25-hydroxyvitamin D levels are strongly related to systolic blood pressure but do not predict future hypertension. *Hypertension* 2010;55:792-8.
- [46] Krause R, Buhning M, Hopfenmuller W, et al. Ultraviolet B and blood pressure. *Lancet* 1998;352:709-10.
- [47] Scragg R, Wishart J, Stewart A, et al. No effect of ultraviolet radiation on blood pressure and other cardiovascular risk factors. *J Hypertens* 2011;29:1749-56.
- [48] Orwoll ES, Oviatt S. Relationship of mineral metabolism and long-term calcium and cholecalciferol supplementation to blood pressure in normotensive men. *Am J Clin Nutr* 1990;52:717-21.
- [49] Pan WH, Wang CY, Li LA, et al. No significant effect of calcium and vitamin D supplementation on blood pressure and calcium metabolism in elderly Chinese. *Chin J Physiol* 1993;36:85-94.
- [50] Major GC, Alarie F, Dore J, et al. Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. *Am J Clin Nutr* 2007;85:54-9.
- [51] Sugden JA, Davies JI, Witham MD, et al. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. *Diabet Med* 2008;25:320-5.
- [52] Zittermann A, Frisch S, Berthold HK, et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. *Am J Clin Nutr* 2009;89:1321-7.
- [53] Daly RM, Nowson CA. Long-term effect of calcium-vitamin D(3) fortified milk on blood pressure and serum lipid concentrations in healthy older men. *Eur J Clin Nutr* 2009;63:993-1000.
- [54] Nagpal J, Pande JN, Bhartia A. A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D₃ supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. *Diabet Med* 2009;26:19-27.
- [55] Margolis KL, Ray RM, Van Horn L, et al. Effect of calcium and vitamin D supplementation on blood pressure: the Women's Health Initiative Randomized Trial. *Hypertension* 2008;52:847-55.
- [56] Jorde R, Sneve M, Torjesen P, et al. No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D₃ for 1 year. *J Intern Med* 2010;267:462-72.
- [57] Scragg R, Khaw KT, Murphy S. Effect of winter oral vitamin D₃ supplementation on cardiovascular risk factors in elderly adults. *Eur J Clin Nutr* 1995;49:640-6.
- [58] Pfeifer M, Begerow B, Minne HW, et al. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. *J Clin Endocrinol Metab* 2001;86:1633-7.
- [59] Witham MD, Nadir MA, Struthers AD. Effect of vitamin D on blood pressure: a systematic review and meta-analysis. *J Hypertens* 2009;27:1948-54.
- [60] Pittas AG, Chung M, Trikalinos T, et al. Systematic review: vitamin D and cardiometabolic outcomes. *Ann Intern Med* 2010;152:307-14.
- [61] Burgaz A, Orsini N, Larsson SC, et al. Blood 25-hydroxyvitamin D concentration and hypertension: a meta-analysis. *Journal of Hypertension* 2010:1.
- [62] Elamin MB, Abu Elnour NO, Elamin KB, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. *J Clin Endocrinol Metab* 2011;96:1931-42.

- [63] Fliser D, Franek E, Fode P, et al. Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans. *Nephrol Dial Transplant* 1997;12: 933-8.
- [64] Morfís L, Smerdely P, Howes LG. Relationship between serum parathyroid hormone levels in the elderly and 24 h ambulatory blood pressures. *J Hypertens* 1997;15: 1271-6.
- [65] Young EW, Morris CD, Holcomb S, et al. Regulation of parathyroid hormone and vitamin D in essential hypertension. *Am J Hypertens* 1995;8:957-64.
- [66] Cravedi P, Ruggenenti P, Remuzzi G. Which antihypertensive drugs are the most nephroprotective and why? *Expert Opin Pharmacother* 2010;11:2651-63.
- [67] Zhang Y, Kong J, Deb DK, et al. Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. *J Am Soc Nephrol* 2010.
- [68] Wang XX, Jiang T, Shen Y, et al. Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism. *Am J Physiol Renal Physiol* 2011;300:F801-10.
- [69] Deb DK, Sun T, Wong KE, et al. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. *Kidney Int* 2010;77:1000-9.
- [70] Zhang Z, Zhang Y, Ning G, et al. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. *Proc Natl Acad Sci U S A* 2008;105: 15896-901.
- [71] Ohara I, Tanimoto M, Gohda T, et al. Effect of combination therapy with angiotensin receptor blocker and 1,25-dihydroxyvitamin D3 in type 2 diabetic nephropathy in KK-Ay/Ta mice. *Nephron Experimental Nephrology* 2011;117: e124-32.
- [72] de Boer IH, Katz R, Chonchol M, et al. Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate. *Clin J Am Soc Nephrol* 2011;6:2141-9.
- [73] Urena-Torres P, Metzger M, Haymann JP, et al. Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD. *Am J Kidney Dis* 2011.
- [74] Forman JP, Williams JS, Fisher ND. Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. *Hypertension* 2010;55:1283-8.
- [75] Barreto DV, Barreto FC, Liabeuf S, et al. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. *Clin J Am Soc Nephrol* 2009;4:1128-35.
- [76] Gonzalez EA, Sachdeva A, Oliver DA, et al. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. *Am J Nephrol* 2004;24: 503-10.
- [77] de Boer IH, Ioannou GN, Kestenbaum B, et al. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). *Am J Kidney Dis* 2007;50:69-77.
- [78] Kandula P, Dobre M, Schold JD, et al. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. *Clin J Am Soc Nephrol* 2011;6:50-62.
- [79] Ravani P, Malberti F, Tripepi G, et al. Vitamin D levels and patient outcome in chronic kidney disease. *Kidney Int* 2009;75:88-95.
- [80] Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. *N Engl J Med* 2003;349:446-56.
- [81] Shoben AB, Rudser KD, de Boer IH, et al. Association of oral calcitriol with improved survival in nondialyzed CKD. *J Am Soc Nephrol* 2008;19:1613-9.
- [82] Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J, et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. *Kidney Int* 2008;74: 1070-8.
- [83] Shoji T, Shinohara K, Kimoto E, et al. Lower risk for cardiovascular mortality in oral 1 α -hydroxy vitamin D3 users in a haemodialysis population. *Nephrol Dial Transplant* 2004;19:179-84.
- [84] Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. *J Am Soc Nephrol* 2005;16:1115-25.
- [85] Wolf M, Betancourt J, Chang Y, et al. Impact of activated vitamin D and race on survival among hemodialysis patients. *J Am Soc Nephrol* 2008;19:1379-88.
- [86] Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. *Kidney Int* 2005;68:2823-8.
- [87] Alborzi P, Patel NA, Peterson C, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. *Hypertension* 2008;52: 249-55.
- [88] Szeto CC, Chow KM, Kwan BC, et al. Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial. *Am J Kidney Dis* 2008;51: 724-31.
- [89] Fishbane S, Chittineni H, Packman M, et al. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. *Am J Kidney Dis* 2009;54:647-52.
- [90] de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. *Lancet* 2010;376:1543-51.
- [91] Kim MJ, Frankel AH, Donaldson M, et al. Oral cholecalciferol decreases albuminuria and urinary TGF- β 1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. *Kidney Int* 2011.
- [92] Joergensen C, Gall MA, Schmedes A, et al. Vitamin D levels and mortality in type 2 diabetes. *Diabetes Care* 2010;33:2238-43.
- [93] Joergensen C, Hovind P, Schmedes A, et al. Vitamin D levels, microvascular complications, and mortality in type 1 diabetes. *Diabetes Care* 2011;34:1081-5.
- [94] Rammos G, Tseke P, Ziakka S. Vitamin D, the renin-angiotensin system, and insulin resistance. *Int Urol Nephrol* 2008;40:419-26.
- [95] Garg R, Hurwitz S, Williams GH, et al. Aldosterone production and insulin resistance in healthy adults. *J Clin Endocrinol Metab* 2010;95:1986-90.
- [96] Lau T, Carlsson PO, Leung PS. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. *Diabetologia* 2004;47:240-8.
- [97] Lupi R, Del Guerra S, Bugliani M, et al. The direct effects of the angiotensin-converting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets. *Eur J Endocrinol* 2006;154:355-61.
- [98] Ko SH, Hong OK, Kim JW, et al. High glucose increases extracellular matrix production in pancreatic stellate cells by activating the renin-angiotensin system. *J Cell Biochem* 2006;98:343-55.
- [99] Leung KK, Leung PS. Effects of hyperglycemia on angiotensin II receptor type 1 expression and insulin secretion in an INS-1E pancreatic beta-cell line. *JOP* 2008;9:290-9.
- [100] Chu KY, Lau T, Carlsson PO, et al. Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. *Diabetes* 2006;55:367-74.

- [101] Tikellis C, Wookey PJ, Candido R, et al. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. *Diabetes* 2004;53:989-97.
- [102] Ko SH, Kwon HS, Kim SR, et al. Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats. *Biochem Biophys Res Commun* 2004;316:114-22.
- [103] McMurray JJ, Holman RR, Haffner SM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. *N Engl J Med* 2010;362:1477-90.
- [104] Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002;359:995-1003.
- [105] Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. *Lancet* 2007;369:201-7.
- [106] Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on the incidence of diabetes. *N Engl J Med* 2006;355:1551-62.
- [107] Cheng Q, Li YC, Boucher BJ, et al. A novel role for vitamin D: modulation of expression and function of the local renin-angiotensin system in mouse pancreatic islets. *Diabetologia* 2011;54:2077-81.
- [108] The EURODIAB Substudy 2 Study Group. Vitamin D supplement in early childhood and risk for type 1 (insulin-dependent) diabetes mellitus. *Diabetologia* 1999;42:51-4.
- [109] Hypponen E, Laara E, Reunanen A, et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. *Lancet* 2001;358:1500-3.
- [110] Baeke F, Takiishi T, Korf H, et al. Vitamin D: modulator of the immune system. *Curr Opin Pharmacol* 2010;10:482-96.
- [111] Simpson M, Brady H, Yin X, et al. No association of vitamin D intake or 25-hydroxyvitamin D levels in childhood with risk of islet autoimmunity and type 1 diabetes: the Diabetes Autoimmunity Study in the Young (DAISY). *Diabetologia* 2011.
- [112] Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. *Diabetes Care* 2004;27:2813-8.
- [113] Kositsawat J, Freeman VL, Gerber BS, et al. Association of A1C levels with vitamin D status in U.S. adults: data from the National Health and Nutrition Examination Survey. *Diabetes Care* 2010;33:1236-8.
- [114] Brock KE, Huang WY, Fraser DR, et al. Diabetes prevalence is associated with serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in US middle-aged Caucasian men and women: a cross-sectional analysis within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *Br J Nutr* 2011;106:339-44.
- [115] Gagnon C, Lu ZX, Magliano DJ, et al. Serum 25-hydroxyvitamin D, calcium intake, and risk of type 2 diabetes after 5 years: results from a national, population-based prospective study (the Australian Diabetes, Obesity and Lifestyle study). *Diabetes Care* 2011;34:1133-8.
- [116] Matsuzawa Y. Adiponectin: a key player in obesity related disorders. *Curr Pharm Des* 2010;16:1896-901.
- [117] Gannage-Yared MH, Chedid R, Khalife S, et al. Vitamin D in relation to metabolic risk factors, insulin sensitivity and adiponectin in a young Middle-Eastern population. *Eur J Endocrinol* 2009;160:965-71.
- [118] Nimitphong H, Chanprasertyothin S, Jongjaroenprasert W, et al. The association between vitamin D status and circulating adiponectin independent of adiposity in subjects with abnormal glucose tolerance. *Endocrine* 2009;36:205-10.
- [119] Vaidya A, Forman JP, Underwood PC, et al. The influence of body mass index and renin-angiotensin-aldosterone system activity on the relationship between 25-hydroxyvitamin D and adiponectin in Caucasian men. *Eur J Endocrinol* 2011;164:995-1002.
- [120] Vaidya A, Williams JS, Forman JP. The independent association between 25-hydroxyvitamin D and adiponectin and its relation with BMI in two large cohorts: the NHS and the HPFS. *Obesity* (Silver Spring) 2011.
- [121] Muscogiuri G, Sorice GP, Priolella A, et al. 25-Hydroxyvitamin D concentration correlates with insulin-sensitivity and BMI in obesity. *Obesity* (Silver Spring) 2010.
- [122] Winters SJ, Chennubhatla R, Wang C, et al. Influence of obesity on vitamin D-binding protein and 25-hydroxy vitamin D levels in African American and white women. *Metabolism* 2009;58:438-42.
- [123] Garg R, Williams GH, Hurwitz S, et al. Low-salt diet increases insulin resistance in healthy subjects. *Metabolism* 2011;60:965-8.
- [124] Perry CG, Palmer T, Cleland SJ, et al. Decreased insulin sensitivity during dietary sodium restriction is not mediated by effects of angiotensin II on insulin action. *Clin Sci (Lond)* 2003;105:187-94.
- [125] Townsend RR, Kapoor S, McFadden CB. Salt intake and insulin sensitivity in healthy human volunteers. *Clin Sci (Lond)* 2007;113:141-8.
- [126] Mattila C, Knekt P, Mannisto S, et al. Serum 25-hydroxyvitamin D concentration and subsequent risk of type 2 diabetes. *Diabetes Care* 2007;30:2569-70.
- [127] Forouhi NG, Luan J, Cooper A, et al. Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000. *Diabetes* 2008;57:2619-25.
- [128] Knekt P, Laaksonen M, Mattila C, et al. Serum vitamin D and subsequent occurrence of type 2 diabetes. *Epidemiology* 2008;19:666-71.
- [129] Liu E, Meigs JB, Pittas AG, et al. Plasma 25-hydroxyvitamin D is associated with markers of the insulin resistant phenotype in nondiabetic adults. *J Nutr* 2009;139:329-34.
- [130] Pittas AG, Sun Q, Manson JE, et al. Plasma 25-hydroxyvitamin D concentration and risk of incident type 2 diabetes in women. *Diabetes Care* 2010;33:2021-3.
- [131] Liu E, Meigs JB, Pittas AG, et al. Predicted 25-hydroxyvitamin D score and incident type 2 diabetes in the Framingham Offspring Study. *Am J Clin Nutr* 2010;91:1627-33.
- [132] de Boer IH, Tinker LF, Connelly S, et al. Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative. *Diabetes Care* 2008;31:701-7.
- [133] Jorde R, Figenschau Y. Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels. *Eur J Nutr* 2009;48:349-54.
- [134] von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient—a randomised, placebo-controlled trial. *Br J Nutr* 2010;103:549-55.
- [135] Nikooyeh B, Neyestani TR, Farvid M, et al. Daily consumption of vitamin D- or vitamin D + calcium-fortified yogurt drink improved glycemic control in patients with type 2 diabetes: a randomized clinical trial. *Am J Clin Nutr* 2011;93:764-71.
- [136] Mitri J, Muraru MD, Pittas AG. Vitamin D and type 2 diabetes: a systematic review. *Eur J Clin Nutr* 2011.